Cure8 research brief
The study tested whether early maternal or family adverse events increase later IBD risk and—using two large Scandinavian birth cohorts with registry follow-up—found no association. That may reassure families worried that early-life family stress alone strongly raises a child’s IBD risk.
Parents and caregivers of young children, pediatric clinicians, and researchers focused on environmental and psychosocial risk factors for IBD.
The study pooled data from two prospective birth cohorts (Norway MoBa and Sweden ABIS) with long follow-up into adolescence/young adulthood and used registry-confirmed IBD outcomes. Reported maternal adverse events during pregnancy and adverse family events by ages 1 or 3 were not linked to higher IBD risk in adjusted models.
The findings address a hypothesized link between early psychosocial stress and immune-mediated disease risk; these cohort data do not support early-life adverse maternal/family events as a driver of IBD onset.
This classification is based on the article abstract. The cohorts used questionnaire-reported adverse events and registry-confirmed IBD diagnoses; observational design and exposure measurement limits mean other stress types, intensities, or biological mediators could still be relevant but were not shown here.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
Finding monogenic causes in infants with congenital diarrheas or VEOIBD can directly affect diagnosis, genetic counseling, and management. Populations with higher consanguinity may have higher diagnostic yields for...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
